Novo Nordisk Q3 Earnings:
- Adj Sales: DKK79.20B (est DKK73.55B)
- Adj Net: DKK25.60B (est DKK21.47B)
- Sees FY Adjusted Sales At CER: -2% To +2% (est -2.35%)
- Sees FY Adjusted Operating Profit At CER: -2% To +2%
- Ozempic Sales: DKK29.71B (est DKK27.19B)
Novo Nordisk raises 2026 outlook as Q3 obesity sales jump 22%